Crinetics Pharmaceuticals, Inc.
CRNX
Rangering i aksjer
#2228
Crinetics Pharmaceuticals, Inc. operates as a clinical-stage pharmaceutical... Crinetics Pharmaceuticals, Inc. operates as a clinical-stage pharmaceutical enterprise, dedicated to the identification, advancement, and market introduction of therapeutic solutions for infrequent endocrine conditions and related tumors. Their flagship drug candidate, Paltusotine, is an orally administered, selective, non-peptide somatostatin receptor type 2 agonist. This compound has concluded its Phase III clinical trials for the treatment of acromegaly, and has also completed Phase II trials targeting carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs). Furthermore, the company's pipeline includes CRN04777, an oral selective non-peptide somatostatin type 5 receptor agonist, which is currently undergoing Phase I clinical trials for congenital hyperinsulinism. Another investigational drug, CRN04894, an oral adrenocorticotrophic hormone antagonist, is in Phase I clinical trials for Cushing's disease and congenital adrenal hyperplasia. Crinetics Pharmaceuticals, Inc. was founded in 2008 and maintains its headquarters in San Diego, California.
Aksjekurs
$84.95
Sist synkronisert: 2026-09-01
Markedsverdi
$9.00B
Endring (1 dag)
0.00%
Endring (1 år)
98.25%
Land
US
Handel Crinetics Pharmaceuticals, Inc. (CRNX)
Kategori
Healthcare
Inntekter for Crinetics Pharmaceuticals, Inc. (CRNX)
Inntekter i Jun 2026 TTM: $42.16M
Ifølge de nyeste økonomiske rapportene til Crinetics Pharmaceuticals, Inc. er selskapets nåværende inntekter (TTM) $42.16M. I 2023 hadde selskapet inntekter på $4.01M en nedgang sammenlignet med inntektene i 2022, som var $4.74M. Inntektene er det totale beløpet et selskap genererer fra salg av varer eller tjenester. I motsetning til fortjeneste trekkes ingen kostnader fra.
Inntektshistorikk for Crinetics Pharmaceuticals, Inc. fra 2016 til 2026
Inntekter ved slutten av hvert år
| År | Inntekter | Endre |
|---|---|---|
| 2026 (TTM) | $42.16M | 3,957.36% |
| 2024 | $1.04M | -74.11% |
| 2023 | $4.01M | -15.28% |
| 2022 | $4.74M | 339.42% |
| 2021 | $1.08M | 1,418.31% |
| 2020 | $71.00K | -94.05% |
| 2019 | $1.19M | -50.86% |
| 2018 | $2.43M | 18.73% |
| 2017 | $2.05M | 247.20% |
| 2016 | $589.00K | 0.00% |
Inntekter for lignende selskaper eller konkurrenter
| Selskap | Inntekter | Forskjell i inntekter | Land |
|---|---|---|---|
| $12.62B | 29,846.63% |
US
|
|
| $2.23B | 5,185.13% |
US
|
|
| $15.74B | 37,247.77% |
AU
|
|
| $6.02B | 14,183.35% |
NL
|
|
| - | - |
CH
|
